PHASE II STUDY OF ADJUVANT NIVOLUMAB IN PATIENTS WITH RESECTED STAGE IIB/IIC MELANOMA (CA209-9CJ)
Study of Nivolumab in Patients with Resected Stage IIB/IIC Melanoma
Sponsor: Thomas Jefferson University
Enrolling: Male and Female Patients
IRB Number: AAAR9042
U.S. Govt. ID: NCT03405155
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will receive Nivolumab infused through a vein in your arm every 4 weeks, for a total of 12 doses. You will receive these doses over a 48 week period.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have no metastatic disease? Yes No
Do you have a negative sentinel lymph node biopsy? Yes No
Do you have stage IIB-IIC melanoma that can be removed by surgery? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162